Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04010045 · ClinicalTrials.gov registry record
REvascularization RateS and Clinical OUtcomes With DABRA Laser. A Long-Term 2-year Study
A clinical trial, sponsored by Ra Medical Systems.
- Terminated
- Registry status
- 19
- Enrollment target
NCT04010045: Clinical Trial study, sponsored by Ra Medical Systems.
NCT04010045 is a clinical trial that was terminated before completion, run by Ra Medical Systems. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04010045 was terminated before completion, sponsored by Ra Medical Systems.
- TERMINATED
- Registry status
- 19 participants
- Enrollment target
Study Summary
This is an observational study of the DABRA Laser System and other medical devices intended for endovascular treatment of peripheral artery disease.
Primary Outcome
Patency of the target lesion at 24 months, as determined by duplex ultrasound.
Interventions
- DEVICE Endovascular Treatment of PAD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2019-05-02 |
| Est. Completion | 2020-10-15 |
Why NCT04010045 stopped before completion
NCT04010045 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Endovascular Treatment of PAD is the first listed.
NCT04010045 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04010045 about?
NCT04010045 is a clinical study titled "REvascularization RateS and Clinical OUtcomes With DABRA Laser. A Long-Term 2-year Study". This is an observational study of the DABRA Laser System and other medical devices intended for endovascular treatment of peripheral artery disease.
What is the current status of trial NCT04010045?
This trial is currently terminated. The enrollment target is 19 participants. The study started on 2019-05-02. Estimated completion is 2020-10-15.
What interventions are being tested in trial NCT04010045?
The interventions under investigation include: Endovascular Treatment of PAD (DEVICE).
Who is sponsoring clinical trial NCT04010045?
This trial is sponsored by Ra Medical Systems, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI